A Meaningful Step Forward for Adults Living with NF1
Health Canada has approved Koselugo (selumetinib) for adults living with NF1 who have symptomatic and inoperable plexiform neurofibromas.
Health Canada has approved Koselugo (selumetinib) for adults living with NF1 who have symptomatic and inoperable plexiform neurofibromas.